The histiocytosis and immune dysregulation treatment team collaborates with researchers at St. Jude and around the world to enhance outcomes for patients with histiocytic disorders.
North American Consortium for Histiocytosis (NACHO)
St. Jude is the coordinating center for NACHO, a multi-institutional consortium that provides support for histiocytosis clinical trials. Carlos Rodriguez-Galindo, MD, director of St. Jude Global Pediatric Medicine, is a founding member and co-leader of NACHO, which is supported by St. Baldrick's Foundation and ALSAC/St. Jude.
Langerhans cell histiocytosis (LCH) and hemophagocytic lymphohistiocytosis (HLH) are quite rare. Thus, a collaborative approach such as that taken by NACHO is necessary to recruit a sufficient number of patients to effectively assess new treatment options.
Laboratory studies on novel therapies for HLH
Current HLH therapies use steroids and chemotherapy to suppress immune activation. These therapies save lives, but improvements in survival rates are still urgently needed. Kim E. Nichols, MD, and her colleagues are using laboratory-based approaches to better understand how HLH develops and to create new and improved treatments.